Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Murat Selçuk, Tufan Çınar, Muhammed Keskin, et al.
Clinical and Experimental Hypertension (2020) Vol. 42, Iss. 8, pp. 738-742
Closed Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

COVID-19 and its cardiovascular effects: a systematic review of prevalence studies
Pierpaolo Pellicori, Gemina Doolub, Chih Wong, et al.
Cochrane library (2021) Vol. 2022, Iss. 4
Open Access | Times Cited: 131
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19
Ranu Baral, Vasiliki Tsampasian, Maciej Dębski, et al.
JAMA Network Open (2021) Vol. 4, Iss. 3, pp. e213594-e213594
Open Access | Times Cited: 114
Challenges for Drug Repurposing in the COVID-19 Pandemic Era
Janet Sultana, Salvatore Crisafulli, Flic Gabbay, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 135
Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients
Carlos Díaz-Arocutipa, Beatriz Melgar-Talavera, A Alvarado-Yarasca, et al.
International Journal of Infectious Diseases (2021) Vol. 110, pp. 374-381
Open Access | Times Cited: 63
The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: A systematic review and meta‐analysis
Yixuan Wang, Baixin Chen, Yun Li, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 3, pp. 1370-1377
Closed Access | Times Cited: 68
A Comprehensive Overview of the COVID-19 Literature: Machine Learning–Based Bibliometric Analysis
Alaa Abd‐Alrazaq, Jens Schneider, Borbála Mifsud, et al.
Journal of Medical Internet Research (2020) Vol. 23, Iss. 3, pp. e23703-e23703
Open Access | Times Cited: 57
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Gianluca Trifirò, Marco Massari, Roberto Da, et al.
Drug Safety (2020) Vol. 43, Iss. 12, pp. 1297-1308
Open Access | Times Cited: 52
N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study
Stelios F. Assimakopoulos, Διαμάντω Αρέθα, Dimitrios Komninos, et al.
Infectious Diseases (2021) Vol. 53, Iss. 11, pp. 847-854
Closed Access | Times Cited: 49
The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis
Jiuyang Xu, Yaqun Teng, Lianhan Shang, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 11, pp. e901-e913
Open Access | Times Cited: 42
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
Murat Öz, Dietrich E. Lorke, Nadine Kabbani
Pharmacology & Therapeutics (2020) Vol. 221, pp. 107750-107750
Open Access | Times Cited: 41
Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, et al.
Journal of Hypertension (2021) Vol. 39, Iss. 4, pp. 784-794
Open Access | Times Cited: 41
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
Syed Shahzad Hasan, Chia Siang Kow, Muhammad Abdul Hadi, et al.
American Journal of Cardiovascular Drugs (2020) Vol. 20, Iss. 6, pp. 571-590
Open Access | Times Cited: 39
Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
Chang Chu, Shufei Zeng, Ahmed A. Hasan, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 6, pp. 2475-2492
Open Access | Times Cited: 36
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Devan Kansagara, Katherine Mackey, Kathryn Vela
Annals of Internal Medicine (2020) Vol. 173, Iss. 3, pp. W66-W66
Open Access | Times Cited: 34
Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis
Mochamad Yusuf Alsagaff, Eka Prasetya Budi Mulia, Irma Maghfirah, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 5, pp. 102210-102210
Open Access | Times Cited: 31
Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
Vasiliki Tsampasian, Natasha Corballis, Vassilios S. Vassiliou
Current Hypertension Reports (2022) Vol. 24, Iss. 10, pp. 425-433
Open Access | Times Cited: 20
Effects of renin‐angiotensin‐aldosterone system inhibitors on disease severity and mortality in patients with COVID‐19: A meta‐analysis
Guoyue Zhang, Yue Wu, Rui Xu, et al.
Journal of Medical Virology (2020) Vol. 93, Iss. 4, pp. 2287-2300
Open Access | Times Cited: 31
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis
Kevin Bryan Lo, Ruchika Bhargav, Grace Salacup, et al.
Expert Review of Cardiovascular Therapy (2020) Vol. 18, Iss. 12, pp. 919-930
Closed Access | Times Cited: 30
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances Taylor, Erik Lampa, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 11
Open Access | Times Cited: 19
Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: Evidence from big data
Mohammad‐Reza Malekpour, Mohsen Abbasi‐Kangevari, Ali Shojaee, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 10
Gastrointestinal Manifestations and Associated Health Outcomes of COVID-19: A Brazilian Experience From the Largest South American Public Hospital
Diogo Turiani Hourneaux de Moura, Ígor Mendonça Proença, Thomas R. McCarty, et al.
Clinics (2020) Vol. 75, pp. e2271-e2271
Open Access | Times Cited: 26
Can C-Reactive Protein to Albumin Ratio Predict In-Hospital Death Rate Due to COVID-19 in Patients With Hypertension?
Faysal Şaylık, Tayyar Akbulut, Şafak Kaya
Angiology (2021) Vol. 72, Iss. 10, pp. 947-952
Open Access | Times Cited: 23
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity
Andrea Spini, Valentina Giudice, Vincenzo Brancaleone, et al.
Pharmacological Research (2021) Vol. 173, pp. 105848-105848
Open Access | Times Cited: 23
Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
Terry Lee, Alessandro Cau, Matthew P. Cheng, et al.
CJC Open (2021) Vol. 3, Iss. 7, pp. 965-975
Open Access | Times Cited: 19
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic
Hongyin Chen, Jiangyun Peng, Tengyao Wang, et al.
Biochemical Pharmacology (2022) Vol. 208, pp. 115370-115370
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top